0001209191-23-009232.txt : 20230214
0001209191-23-009232.hdr.sgml : 20230214
20230214170854
ACCESSION NUMBER: 0001209191-23-009232
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230210
FILED AS OF DATE: 20230214
DATE AS OF CHANGE: 20230214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanna Bastiano
CENTRAL INDEX KEY: 0001829069
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 23631401
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-10
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001829069
Sanna Bastiano
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Cell & Genetic Therapies
Common Stock
2023-02-10
4
F
0
902
294.33
D
66368
D
Common Stock
2023-02-13
4
F
0
4340
298.26
D
62028
D
Common Stock
2023-02-13
4
S
0
113
300.39
D
61915
D
Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $300.39 (range $300.00 to $300.79).
/s/ Christiana Stevenson, Attorney-in-Fact
2023-02-14